Replimune Group (NASDAQ:REPL) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Replimune Group from “sell” to “hold,” while the broader analyst consensus remains “Moderate Buy” with a $14.33 target price.
• REPL shares opened at $17.61, near their 52-week high of $18.27, and the company reported a quarterly loss of $0.54 per share—better than the consensus estimate of a $0.78 loss.
• Insiders sold shares primarily to cover tax obligations, while institutional investors own a substantial 92.53% of the company.

Replimune Group (NASDAQ:REPL - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday, Wall Street Zen reports.

Several other equities research analysts also recently weighed in on REPL. Piper Sandler raised Replimune Group from a "hold" rating to a "strong-buy" rating in a report on Friday, July 31st. Wedbush upgraded shares of Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price objective on the stock in a report on Friday, August 7th. Wolfe Research upgraded shares of Replimune Group to an "outperform" rating in a report on Tuesday, August 4th. Leerink Partners increased their price objective on shares of Replimune Group from $19.00 to $31.00 and gave the company an "outperform" rating in a research report on Thursday. Finally, JPMorgan Chase & Co. lifted their target price on shares of Replimune Group from $20.00 to $21.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $14.33.

Replimune Group Trading Up 1.3%

Replimune Group stock opened at $17.61 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 7.11 and a quick ratio of 5.23. Replimune Group has a 1-year low of $1.50 and a 1-year high of $18.27. The business has a fifty day moving average price of $13.58 and a 200-day moving average price of $9.35.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.24. As a group, equities analysts anticipate that Replimune Group will post -2.74 EPS for the current year.

Insider Transactions at Replimune Group

In related news, CEO Sushil Patel sold 39,341 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $510,252.77. Following the transaction, the chief executive officer owned 708,151 shares in the company, valued at approximately $9,184,718.47. This represents a 5.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,467.59. Following the completion of the transaction, the insider owned 224,215 shares in the company, valued at approximately $2,908,068.55. This trade represents a 4.86% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 79,124 shares of company stock worth $1,038,364. 5.40% of the stock is owned by insiders.

Institutional Trading of Replimune Group

Several large investors have recently made changes to their positions in REPL. Mirae Asset Global Investments Co. Ltd. acquired a new position in Replimune Group in the third quarter valued at approximately $64,000. Allworth Financial LP purchased a new stake in Replimune Group in the 2nd quarter worth approximately $62,000. Essential Partners LLC grew its stake in shares of Replimune Group by 562,400.0% during the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company's stock worth $43,000 after purchasing an additional 5,624 shares during the period. Legal & General Group Plc acquired a new stake in shares of Replimune Group during the 2nd quarter worth approximately $85,000. Finally, WINTON GROUP Ltd acquired a new stake in shares of Replimune Group during the 2nd quarter worth approximately $115,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company's approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune's lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.